Guthrie Eyes FDA Oversight, Price Transparency, Innovation Next Congress

By Beth Wang / December 8, 2022 at 1:05 PM
Republican Rep. Brett Guthrie (KY), who is in line to lead the House Energy & Commerce health subcommittee next Congress, told Inside Health Policy that if tapped as chair he would focus on medical product innovation, price transparency and health agency oversight, including looking into FDA’s use of emergency use authorizations to ascertain lessons for future pandemics and the agency’s response to the infant formula shortage to improve its handling of ongoing drug supply issues. Guthrie, the ranking Republican...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.